Last Updated: 19 May 2026
Nourish has completed a $100 million Series C funding round to expand its healthcare services for Americans with long term nutritional conditions. The company operates a virtual clinic focused on metabolic health and connects patients with registered dietitians. This funding will expand care. Chief executive officer Aidan Dewar cofounded the organization, which now includes over 10,000 registered dietitians across all 50 states after tripling its business size year over year.
Chronic health conditions affect an estimated 194 million adults in the United States according to data from 2023. These long term illnesses, including common diseases like diabetes and high blood pressure, drain billions from the economy every year while absorbing 80 percent of all Medicaid spending. Unfortunately, the current medical system often fails to provide the continuous preventive care that these patients need. Nourish intends to bridge this gap by combining human medical providers with automated software tools to lower treatment costs. Management believes this approach works.
Many prominent investment firms participated in this latest funding round, which was officially led by Menlo Ventures. Other financial contributors included Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. This capital brings total funding to $215 million. Partner J.P. Sanday joins the board.
Medical institutions in the United States were historically designed to treat sudden illnesses such as infections, physical injuries, and emergency medical situations. Conversely, managing chronic conditions requires long term behavioral adjustments, routine tracking, and coordinated medical attention spanning several consecutive months or years. This persistent model contrasts sharply with the traditional approach of relying on isolated doctor appointments. Such continuous care has historically been fragmented, expensive, or completely unavailable to ordinary individuals. Access remains a persistent challenge.
A research report published in December 2025 by the Partnership to Fight Chronic Disease highlights the massive economic toll of long term illnesses. Projections indicate that chronic conditions will cost the United States up to $47 trillion between 2024 and 2039, including $2.2 trillion annually in medical care. The data also reveals that five percent of patients drive nearly half of all healthcare spending due to having three or more conditions. These heavy financial statistics underscore the economic argument for the early preventive care models that Nourish is trying to establish. These numbers remain incredibly high.
"Chronic disease is the central failure of U.S. healthcare: nearly 200 million Americans affected, trillions spent, and outcomes that still don't move. What Nourish has built in four years is remarkable: a care model that actually bends the cost curve, with 10,000 dietitians, deep payer relationships, and clinical outcomes patients stick with. Most companies get one of those things right. Nourish has all of them. We're proud to lead this round."
J.P. Sanday, Partner at Menlo Ventures
The company has outlined a specific plan to distribute the $100 million across four core operational areas. These goals include expanding the clinical network, developing new artificial intelligence software, scaling the metabolic clinic model, and deepening insurance partnerships. Every single one of these individual initiatives is designed to achieve the same primary objective. The organization wants to deliver more care to patients at a lower cost per outcome. This plan requires meticulous execution.
Software development represents a significant portion of the new corporate budget. Nourish has already built an automated health assistant into its patient mobile application, which attracts hundreds of thousands of active users every month. For medical professionals, the company provides automated tools that highlight real time clinical insights and handle administrative duties. This software handles time consuming paperwork so that registered dietitians can focus entirely on patients. By expanding these automated systems, the virtual clinic can assist more clients without needing to hire an equivalent number of new employees. Automated tools assist staff growth.
Medical support for patients taking GLP-1 medications represents another major expansion target for the business. These prescription drugs are currently widely popular for weight loss and diabetes management, but long term patient adherence remains a documented challenge. A medical study published in January 2025 in the journal JAMA Network Open revealed that most individuals discontinue these medications within a single year. Dropout rates were particularly high among weight loss patients. Nourish combines medical prescriptions for these drugs with intensive nutritional counseling to help individuals maintain their health improvements over time. This approach provides steady guidance. This integrated structure helps patients succeed.
Operating as an online medical clinic for the past four years, the company specializes entirely in metabolic health services. New patients are paired with a registered dietitian for remote video consultations and personalized guidance. Each individual receives a customized treatment plan tailored to their specific medical background and daily lifestyle habits. Depending on individual requirements, these wellness plans can incorporate diagnostic blood tests, prescription medications, and ongoing communication with the patient's existing primary care physicians. Automated software assistants remain available between regular appointments to reinforce positive choices. Patients receive continuous daily support.
Specific clinical measurements demonstrate the impact of this structured approach on patient wellness according to company reports. Patients using the platform experience an average reduction of 8 percent in total body weight alongside a 1.3 point drop in blood sugar levels. Average drops of 31 points in harmful LDL cholesterol and 23 points in systolic blood pressure were also recorded. These improvements translate to over $2,000 in annual savings for insurance providers per patient. Hundreds of insurance health plans have partnered with the organization due to these figures. Financial savings accumulate very quickly.
"Chronic disease is the largest cost driver in U.S. healthcare, and the system still isn't built to treat it. Too often, patients get expensive, reactive, fragmented care that doesn't actually make them healthier. We've built the care model and technology to change that, driving the behavior and lifestyle change that delivers real clinical outcomes at a low cost and great patient experience. The demand from patients, providers, health plans, employers, and health systems has never been clearer, and this round positions us to meet it at scale."
Aidan Dewar, Co-Founder and CEO of Nourish
Millions of individual telehealth consultations have been completed through the platform since the company began operations. The organization has formed partnerships with more than 250 health systems whose medical professionals refer hundreds of thousands of patients to the service. Residents living in all 50 states can access these virtual clinic services from their homes. Health insurance plans cover consultations for most individuals, resulting in no out of pocket costs.
Accumulated funding for the virtual health platform now stands at $215 million following the successful completion of this recent Series C financial transaction. Because Menlo Ventures led the transaction, partner J.P. Sanday will join the corporate board of directors. Other participating investment groups include Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, and Maverick Ventures. Additional contributions came from Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. The company did not disclose the financial details or individual amounts raised during its earlier venture capital rounds.
